Advertisement Tosoh Bioscience Releases New Hydroxyapatite with Ca++Pure-HA - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
More info about Tosoh Bioscience

Tosoh Bioscience Releases New Hydroxyapatite with Ca++Pure-HA

Tosoh Bioscience has introduced a new hydroxyapatite medium to its product portfolio.

Ca⁺⁺Pure-HA provides exceptional separation properties and unequalled selectivity, as well as a resolution for the purification of multiple classes of biomolecules. It supports the continuous effort of the pharmaceutical industry to reduce the manufacturing costs of biological drugs.

A hydroxyapatite resin used in the chromatographic separation of biomolecules, Ca⁺⁺Pure-HA’s key applications include the purification of monoclonal and polyclonal antibodies such as Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), antibody fragments, fusion and phosphoproteins, as well as the separation of single-stranded and double-stranded DNA.

Ca⁺⁺Pure-HA has demonstrated dynamic binding capacity (DBC) at 5% breakthrough of 55mg monoclonal antibody (mAb) per mg at five minute residence time.

In addition, Ca⁺⁺Pure-HA has been sintered at high temperatures for increased mechanical and pH stability, allowing it to withstand the rigours of industrial-scale applications. The robust nature of Ca⁺⁺Pure-HA offers the flexibility to use this medium at any stage in a process from capture to final polishing.

To receive more information visit Tosoh’s website or make an enquiry using the form on this page.